Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 3
2016 5
2017 5
2018 4
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Anti-cancer activity of amorphous curcumin preparation in patient-derived colorectal cancer organoids.
Elbadawy M, Hayashi K, Ayame H, Ishihara Y, Abugomaa A, Shibutani M, Hayashi SM, Hazama S, Takenouchi H, Nakajima M, Tsunedomi R, Suzuki N, Nagano H, Shinohara Y, Kaneda M, Yamawaki H, Usui T, Sasaki K. Elbadawy M, et al. Among authors: takenouchi h. Biomed Pharmacother. 2021 Oct;142:112043. doi: 10.1016/j.biopha.2021.112043. Epub 2021 Aug 16. Biomed Pharmacother. 2021. PMID: 34411919 Free article.
Overexpression of miR‑221 and miR‑222 in the cancer stroma is associated with malignant potential in colorectal cancer.
Iida M, Hazama S, Tsunedomi R, Tanaka H, Takenouchi H, Kanekiyo S, Tokumitsu Y, Tomochika S, Tokuhisa Y, Sakamoto K, Suzuki N, Takeda S, Ueno T, Yamamoto S, Yoshino S, Fujita K, Kuroda M, Nagano H. Iida M, et al. Among authors: takenouchi h. Oncol Rep. 2018 Sep;40(3):1621-1631. doi: 10.3892/or.2018.6575. Epub 2018 Jul 13. Oncol Rep. 2018. PMID: 30015977
IgG response to MHC class I epitope peptides is a quantitative predictive biomarker in the early course of treatment of colorectal cancer using therapeutic peptides.
Kanekiyo S, Hazama S, Takenouchi H, Nakajima M, Shindo Y, Matsui H, Tokumitsu Y, Tomochika S, Tsunedomi R, Tokuhisa Y, Iida M, Sakamoto K, Suzuki N, Takeda S, Yamamoto S, Yoshino S, Okuno K, Udaka K, Kawakami Y, Matsueda S, Ito K, Nagano H. Kanekiyo S, et al. Among authors: takenouchi h. Oncol Rep. 2018 May;39(5):2385-2392. doi: 10.3892/or.2018.6288. Epub 2018 Mar 1. Oncol Rep. 2018. PMID: 29498403 Clinical Trial.
Stemness Is Enhanced in Gastric Cancer by a SET/PP2A/E2F1 Axis.
Enjoji S, Yabe R, Tsuji S, Yoshimura K, Kawasaki H, Sakurai M, Sakai Y, Takenouchi H, Yoshino S, Hazama S, Nagano H, Oshima H, Oshima M, Vitek MP, Matsuura T, Hippo Y, Usui T, Ohama T, Sato K. Enjoji S, et al. Among authors: takenouchi h. Mol Cancer Res. 2018 Mar;16(3):554-563. doi: 10.1158/1541-7786.MCR-17-0393. Epub 2018 Jan 12. Mol Cancer Res. 2018. PMID: 29330298
miR-125b-1 and miR-378a are predictive biomarkers for the efficacy of vaccine treatment against colorectal cancer.
Tanaka H, Hazama S, Iida M, Tsunedomi R, Takenouchi H, Nakajima M, Tokumitsu Y, Kanekiyo S, Shindo Y, Tomochika S, Tokuhisa Y, Sakamoto K, Suzuki N, Takeda S, Yamamoto S, Yoshino S, Ueno T, Hamamoto Y, Fujita Y, Tanaka H, Tahara K, Shimizu R, Okuno K, Fujita K, Kuroda M, Nakamura Y, Nagano H. Tanaka H, et al. Among authors: takenouchi h. Cancer Sci. 2017 Nov;108(11):2229-2238. doi: 10.1111/cas.13390. Epub 2017 Sep 22. Cancer Sci. 2017. PMID: 28859241 Free PMC article. Clinical Trial.
miR-196b, miR-378a and miR-486 are predictive biomarkers for the efficacy of vaccine treatment in colorectal cancer.
Shindo Y, Hazama S, Nakamura Y, Inoue Y, Kanekiyo S, Suzuki N, Takenouchi H, Tsunedomi R, Nakajima M, Ueno T, Takeda S, Yoshino S, Okuno K, Fujita Y, Hamamoto Y, Kawakami Y, Oka M, Nagano H. Shindo Y, et al. Among authors: takenouchi h. Oncol Lett. 2017 Aug;14(2):1355-1362. doi: 10.3892/ol.2017.6303. Epub 2017 Jun 2. Oncol Lett. 2017. PMID: 28789351 Free PMC article.
Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer.
Shindo Y, Hazama S, Suzuki N, Iguchi H, Uesugi K, Tanaka H, Aruga A, Hatori T, Ishizaki H, Umeda Y, Fujiwara T, Ikemoto T, Shimada M, Yoshimatsu K, Takenouchi H, Matsui H, Kanekiyo S, Iida M, Koki Y, Arima H, Furukawa H, Ueno T, Yoshino S, Fujita T, Kawakami Y, Nakamura Y, Oka M, Nagano H. Shindo Y, et al. Among authors: takenouchi h. J Exp Clin Cancer Res. 2017 Feb 28;36(1):36. doi: 10.1186/s13046-017-0509-1. J Exp Clin Cancer Res. 2017. PMID: 28241889 Free PMC article. Clinical Trial.
Establishment of a Novel Model for Anticancer Drug Resistance in Three-Dimensional Primary Culture of Tumor Microenvironment.
Usui T, Sakurai M, Enjoji S, Kawasaki H, Umata K, Ohama T, Fujiwara N, Yabe R, Tsuji S, Yamawaki H, Hazama S, Takenouchi H, Nakajima M, Tsunedomi R, Suzuki N, Nagano H, Sato K. Usui T, et al. Among authors: takenouchi h. Stem Cells Int. 2016;2016:7053872. doi: 10.1155/2016/7053872. Epub 2016 Dec 29. Stem Cells Int. 2016. PMID: 28119740 Free PMC article.
MicroRNA-6826 and -6875 in plasma are valuable non‑invasive biomarkers that predict the efficacy of vaccine treatment against metastatic colorectal cancer.
Kijima T, Hazama S, Tsunedomi R, Tanaka H, Takenouchi H, Kanekiyo S, Inoue Y, Nakashima M, Iida M, Sakamoto K, Suzuki N, Takeda S, Ueno T, Yamamoto S, Yoshino S, Okuno K, Nagano H. Kijima T, et al. Among authors: takenouchi h. Oncol Rep. 2017 Jan;37(1):23-30. doi: 10.3892/or.2016.5267. Epub 2016 Nov 22. Oncol Rep. 2017. PMID: 27878288 Free PMC article. Clinical Trial.
16 results